Puma Biotechnology (PBYI) Assets (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly Assets came in at $192.7 million in Q1 2026, down 1.77% YoY from $196.2 million in Q1 2025, and down 10.91% on a QoQ basis from $216.3 million in Q4 2025.
Puma Biotechnology (PBYI) Assets (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of Assets data on file, last reported at $192.7 million in Q1 2026.
- Quarterly Assets fell 1.77% year-over-year to $192.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $192.7 million (down 1.77% YoY) and the FY2025 annual result came in at $216.3 million, up 1.39% from the prior year.
- Assets declined to $192.7 million in Q1 2026, from $216.3 million in the prior quarter.
- In the past five years, Assets ranged from a high of $230.5 million in Q4 2023 to a low of $192.7 million in Q1 2026.
- A 5-year average of $206.0 million and a median of $202.9 million in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets fell 25.52% — and 2024, when it gained 9.12%.
- Tracing PBYI's Assets over 5 years: stood at $222.1 million in 2022, then advanced by 3.81% to $230.5 million in 2023, then slipped by 7.46% to $213.3 million in 2024, then gained by 1.39% to $216.3 million in 2025, then decreased by 10.91% to $192.7 million in 2026.
- The last three Assets figures came in at $192.7 million (Q1 2026), $216.3 million (Q4 2025), and $202.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 192.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.74 Mn |
| Mar 31, 2026 | 192.70 Mn |
| Dec 31, 2025 | 216.30 Mn |
| Sep 30, 2025 | 202.86 Mn |
| Jun 30, 2025 | 194.92 Mn |
| Mar 31, 2025 | 196.18 Mn |
| Dec 31, 2024 | 213.33 Mn |
| Sep 30, 2024 | 220.72 Mn |
| Jun 30, 2024 | 205.00 Mn |
| Mar 31, 2024 | 214.15 Mn |
| Dec 31, 2023 | 230.53 Mn |
| Sep 30, 2023 | 203.61 Mn |
| Jun 30, 2023 | 200.49 Mn |
| Mar 31, 2023 | 196.26 Mn |
| Dec 31, 2022 | 222.06 Mn |
| Sep 30, 2022 | 198.77 Mn |
| Jun 30, 2022 | 193.65 Mn |
| Mar 31, 2022 | 200.69 Mn |
| Dec 31, 2021 | 226.59 Mn |
| Sep 30, 2021 | 226.29 Mn |